Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Clinical trial NCT02475681 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02475681
Sponsor: Acerta Pharma BV
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2015-06-26
Primary completion: 2019-02-08
Enrollment: 535

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.